Novo-Nordisk A/S
NVO Real Time Price USDRecent trades of NVO by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in NVO holdings by institutional investors
Quarterly net insider trading by NVO's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$1,300,000 Jul 20, 2026 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$1,290,000 Apr 20, 2026 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$2,120,000 Jan 20, 2026 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$1,730,000 Oct 20, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$1,050,000 Jul 16, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$2,330,000 Apr 18, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark
-
$1,240,000 Jan 17, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark
-
$780,000 Oct 18, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$1,060,000 Jul 19, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$1,490,000 Apr 18, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$60,000 Feb 07, 2024 Issue: Budget/Appropriations Pharmacy Medicare/Medicaid Health Issues
-
$600,000 Oct 19, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
Former government officials who have lobbied for NVO
104 former government officials from 64 congressional offices at 20 lobbying firms have lobbied for NVO, most recently Jul 21, 2026.
-
Daniel Todd Senate Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid
-
Paul Edattel House Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg -
Nicholas Uehlecke House Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee
-
Katherine Cotton House Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie -
Eric Bergren House Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
-
Nicolas Magallanes House Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander -
Christopher Wilcox House LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings -
Jeanne Haggerty Senate Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
NVO Estimated quarterly lobbying spending
NVO Revenue by Segment or Geography
New NVO patent grants
-
Patent Title: Tablet Aug. 25, 2026
-
Patent Title: Injection device Jun. 02, 2026
-
Patent Title: Pill Mar. 24, 2026
-
Patent Title: Injection device Sep. 09, 2025
-
Patent Title: Injection device Feb. 18, 2025
-
Patent Title: Pill bottle Oct. 29, 2024
-
Patent Title: Pill Aug. 20, 2024
-
Patent Title: Logging device for drug delivery device Feb. 28, 2023
-
Patent Title: Injection device Jun. 21, 2022
-
Patent Title: Injector pen May. 24, 2022
-
Patent Title: Tablet formulation comprising semaglutide and a delivery agent Jun. 12, 2018
-
Patent Title: Stable glp-1 based glp-1/glucagon receptor co-agonists Jun. 05, 2018
-
Patent Title: Enterokinase cleavable polypeptides May. 29, 2018
-
Patent Title: Factor viii polypeptide titers in cell cultures May. 29, 2018
-
Patent Title: Liraglutide in cardiovascular conditions May. 15, 2018
-
Patent Title: Stable glucagon analogues and use for treatment of hypoglycaemia May. 08, 2018
-
Patent Title: Frontloaded drug delivery device with dynamic axial stop feature May. 01, 2018
-
Patent Title: Mic-1 fusion proteins and uses thereof May. 01, 2018
-
Patent Title: Medical injection device comprising a secondary safety limiter Apr. 24, 2018
-
Patent Title: Medical device and cartridge Apr. 24, 2018
-
Patent Title: Human cd30 ligand antigen binding proteins Mar. 27, 2018
-
Patent Title: Glp-1 compounds Mar. 20, 2018
-
Patent Title: Arrangement for sequential delivery of fluid volumes Mar. 20, 2018
-
Patent Title: Antibodies that bind urokinase plasminogen activator Mar. 06, 2018
-
Patent Title: Injection device with a sliding scale Feb. 27, 2018
-
Patent Title: Medical injection device Feb. 27, 2018
-
Patent Title: Spring driven injection device Feb. 27, 2018
-
Patent Title: Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor Feb. 20, 2018
-
Patent Title: Derivative of an insulin analogue Feb. 20, 2018
-
Patent Title: Fgf21 derivatives and uses thereof Feb. 20, 2018
-
Patent Title: Drug filled delivery assembly Feb. 13, 2018
-
Patent Title: Method of treating diabetes mellitus Feb. 06, 2018
-
Patent Title: Anti-kir antibodies, formulations, and uses thereof Jan. 30, 2018
-
Patent Title: Injection device with an end of dose feedback mechanism Jan. 09, 2018
-
Patent Title: Spring driven injection device Jan. 09, 2018
-
Patent Title: Injection device Jan. 02, 2018
-
Patent Title: Dial-down mechanism for wind-up pen Apr. 11, 2017
-
Patent Title: Insulin derivatives Oct. 04, 2016
-
Patent Title: Injection device Sep. 06, 2016
-
Patent Title: Injector display with graphical user interface Jul. 26, 2016
-
Patent Title: Injection device Jun. 07, 2016
-
Patent Title: Container for medical purposes Dec. 29, 2015
-
Patent Title: Aryl carbonyl derivatives as therapeutic agents Sep. 15, 2015
-
Patent Title: Injection device Jul. 14, 2015
-
Patent Title: Injection device May. 19, 2015
-
Patent Title: Injection device Mar. 17, 2015
-
Patent Title: Heteroaryl-ureas and their use as glucokinase activators Oct. 07, 2014
-
Patent Title: Needle hub Jan. 29, 2013
-
Patent Title: Injection syringe Nov. 27, 2012
-
Patent Title: Dose setting limiter Nov. 23, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded to NVO from public contracts
Recent insights relating to NVO
Recent picks made for NVO stock on CNBC
ETFs with the largest estimated holdings in NVO
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $NVO stock a Buy, Sell, or Hold?
- What is the price target for $NVO stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $NVO stock?
- Who owns the most shares of $NVO stock?
- What funds own $NVO stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NVO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Novo-Nordisk A/S (NVO) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Novo-Nordisk A/S (NVO).
Quiver Premium charts NVO's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at NVO, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|